Circulating levels of HER-2/neu oncoprotein in breast cancer

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 1, 2012, Pages 5-21

  Molina, Rafael ^a   Escudero, Jose M ^a   Muñoz, Montse ^a   Augé, Jose M ^a   Filella, Xavier ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Breast cancer; CA 15.3; Carcinoembryonic antigen (CEA); HER 2 neu; Oncoproteins; Tumor markers

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CA 15-3 ANTIGEN; CAPECITABINE; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; LAPATINIB; MEGESTROL ACETATE; METHOTREXATE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER;

ADVANCED CANCER; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CARDIOTOXICITY; DIAGNOSTIC VALUE; DIARRHEA; EARLY DIAGNOSIS; HUMAN; IMMUNOASSAY; LIVER DISEASE; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; NAUSEA; OVARY CANCER; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; RASH; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; HUMANS; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84857879999     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.822     Document Type: Review

References (180)

1. Olayioye MA, Neve RM, Lane HA, Hynes NE. The erbB signalling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67. (Pubitemid 30428195)
2. Ross JS, Fletcher JA. HER-2/neu (C-erbB-2) gene and protein in breast cancer. Am J Clin Pathol 1999;112:53-67.
3. Potter CR, van Doele S, van de Vijver MJ, Pauwels C, Maertens G, De Boever J, et al. The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology 1989;15:351-62. (Pubitemid 19253154)
4. Slamon D, Pegram M. Rationale for Trastuzumab (Herceptin) in adjuvant breast cancer trials. Sem Oncol 2001;28:13-9.
5. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer. European Group on Tumor Marker Recommendations. Tumor Biol 2005;26:281-93. (Pubitemid 41619458)
6. Bast RC, Ravdin P, Hayes DF, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology Tumor Markers Expert Panel: 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American society of clinical oncology. J Clin Oncol 2001;19:1865-78 (Pubitemid 32230890)
7. Harris l, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. Recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.
8. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307-25. (Pubitemid 36929717)
9. Ocaña A, Cruz JJ, Pandiella A. Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance. Am J Clin Oncol 2006;29:90-5. (Pubitemid 44356722)
10. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357:1496-506. (Pubitemid 47572635)
11. Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overex-presses HER-2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
12. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-56. (Pubitemid 32366985)
13. Piccart MJ, Di Leo A, Hamilton A. HER2: a predictive factor ready to use in the daily management of breast cancer patients? Eur J Cancer 2000;36:1755-61. (Pubitemid 30639494)
14. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et al. Phase II study of receptor-enhanced chemo-sensitivity using recombinant humanized anti-p185 HER-2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71. (Pubitemid 28363029)
15. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapa-tinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Br Cancer Res Treat 2008;112:533-43.
16. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer: a randomized controlled trial. Lancet 2007;369:29-36. (Pubitemid 46039831)
17. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26. (Pubitemid 34111379)
18. Cobleigh MA,Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic breast cancer. J Clin Oncol 1999;17:2639-48. (Pubitemid 29415219)
19. Emens LA. Trastuzumab: targeted therapy for the management of HER-2/neu overexpressing metastatic breast cancer. Am J Ther 2005;12:243-53. (Pubitemid 40825130)
20. Singer CF, Köstler WJ, Hudelist G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Biochim Biophys Acta 2008;1786:105-13.
21. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER-2/neu overexpression stage II or III breast cancer: a pilot study. J Clin Oncol 2003;21:46-53.
22. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xeno-graphs. Cancer Res 1998;58:2825-31. (Pubitemid 28311914)
23. Mary M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the effi-cacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74. (Pubitemid 46207001)
24. Von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:1999-2006.
25. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. N Engl J Med 2005;353:1673-84. (Pubitemid 41464706)
26. Kroep JR, Linn SC, Boven E, Bloemendal HJ, Baas J, Mandjes IA, et al. Lapatinib: clinical benefit in patients with HER-2/neu positive advanced breast cancer. Neth J Med 2010;68:371-6.
27. Geyer CE, Foster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capacetabinefor HER-2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43. (Pubitemid 46021510)
28. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26:2995-3005.
29. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, et al. Phase III, double blind, randomized study comparing lapa-tinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26:5544-52.
30. Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007;12:756-65. (Pubitemid 47328219)
31. DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, et al. Influence of activate state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide doxorubicin, and fluoruracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol 2008;26:2364-72.
32. Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ, et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 1998;58:5123-9. (Pubitemid 28521172)
33. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER-2/neu overexpressing breast cancer. Ann Oncol 2007;18:977-84. (Pubitemid 47050487)
34. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (Herceptin), a humanized anti-Her-2 receptor monoclonal antibody, inhibits basal and activated HER-2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61:4744-9. (Pubitemid 32691885)
35. Fergerbaum JH, Garcia-Closas M, Hewitt SM, Lissowska J, Sakoda LC, Sherman ME. Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev 2004;13:667-2.
36. Tanner M, Järvinen P, Isola J. Amplification of her-2/neu and topoisomerase II in primary and metastatic breast cancer. Cancer Res 2001;61:5345-8. (Pubitemid 32694907)
37. Simon R, Nocito A, Hübscher T, Bucher C, Torhorst J, Schraml P, et al. Patterns of HER-2/neu amplification and overexpres-sion in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93:1141-6. (Pubitemid 32780965)
38. Andersen TI, Paus E, Nesland JM, McKenzie SJ, Borrensen AL. Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. Acta Oncol 1995;34:499-504.
39. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Potential clinical utility of serum HER-2/neu oncopro-tein concentrations in patients with breast cancer. Clin Chem 2003;49:1579-98. (Pubitemid 37194212)
40. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Monitoring the circulating levels of the HER-2/neu oncoprotein in breast cancer. Clin Breast Cancer 2004;5:105-16. (Pubitemid 39029201)
41. Tse C, Brault D, Gligorov J, Antoine M, Neumann R, Lotz JP, et al. Evaluation of the quantitative analytical methods real time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. Clin Chem 2005;51:1093-101. (Pubitemid 43079384)
42. Teixeira MR, Pandis N, Berdi G, Andersen JA, Heim S. Karyotypic comparisons of multiple tumours and macroscopi-cally normal surrounding tissue samples from patients with breast cancer. Cancer Res 1996;56:855-9. (Pubitemid 26055477)
43. Pandis N, Jin Y, Gorunova L, Petersson C, Bardi G, Idvall I, et al. Chromosome analysis of 97 primary breast carcinomas: iden-tification of eight karyotypic subgroups. Genes Chromosome Cancer 1995;12:173-85.
44. Kuukasjärvi T, Karhu R, Tanner M, Kähkönen M, Schäffer A, Nupponen N, et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 1997;57:1597-604. (Pubitemid 27175581)
45. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinomas. Cancer 2005;103:1763-9. (Pubitemid 40563246)
46. Masood S, Bui MM. Assessment of HER-2/neu overexpression in primary breast cancers and their metastatic lesions: an immu-nohistochemical study. Ann Clin Lab Sci 2000;30:259-65. (Pubitemid 30620800)
47. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary Al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005;95:552-6. (Pubitemid 43079998)
48. Regitnig P, Schippinger W, Lindbauer M, Samonigg H, Lax SF. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 2004;203:918-26. (Pubitemid 39089280)
49. Edgerton SM, Moore D, Merkel D, Thor AD. ErbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 2003;11:214-21. (Pubitemid 37082057)
50. Gancberg D, DiLeo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, et al. Comparison of HER-status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036-43.
51. Lower EE, Glass E, Blau R, Harman S. HER-2/neu expression in primary and metastatic breast cancer. Br Cancer Res Treat 2009;113:301-6.
52. Shimizu C, Fukutomi T, Tsuda H, Akashi-Tanaka S, Watanabe T, Nanasawa T, et al. C-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 2000;73:17-20. (Pubitemid 30067528)
53. Iglehart JD, Kraus MH, Langton BC, Huper G, Kerns BJ, Marks JR. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 1990;50:6701-7. (Pubitemid 20348803)
54. Krogerus LA, Leivonen M. HER-2/neu oncogene expression in advanced breast cancer. Cancer Detect Prev 2001;25:1-7.
55. Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H. Amplification of HER-2/neu gene in HER-2/neu overexpressing and non-overexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 2002;15:116-24. (Pubitemid 34171321)
56. Vincent-Salomon A, Jouve M, Genin P, Fréneaux P, Sigal-Zafrani B, Caly M, et al. HER-2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002;94:2169-73. (Pubitemid 34411973)
57. Pectasides D, Gaglia A, Arapantoni-Dadioti P, Bobota A, Valavanis C, Kostopoulou V, et al. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res 2006;26:647-54. (Pubitemid 43206030)
58. Varga Z, Caduff R, Pestalozzi B. Stability of the HER-2/neu gene after primary chemotherapy in advanced breast cancer. Virchows Arch 2005;446:136-41. (Pubitemid 40385643)
59. Hayes DF, Walker TM, Singh B, Vitetta ES, Uhr JW, Gross S, et al. Monitoring expression of HER2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 2002;21:1111-7.
60. Aguilar Z, Slamon DJ. The transmembrane heregulin precursor is functionally active. J Biol Chem 2001;276:44099-107.
61. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001;10:139-52. (Pubitemid 32808108)
62. Zabrecky JR, Lam T, Mckenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinomas cells SKBR-3. J Biol Chem 1991;266:1716-20. (Pubitemid 21908361)
63. Liu PC, Liu X, Li Y, Covington M, Wynn R, Huber R, et al. Identification of ADAM10 as a major source of HER-2 ectodo-main sheddase activity in HER-2 overexpressing breast cancer cells. Cancer Biol Ther 2006;5:657-64. (Pubitemid 44024721)
64. Yuan P, Xu BH, Chu DT. Correlation between serum HER-2/neu oncoprotein and patients with breast cancer. Chin Med Sci 2004;19:212-5. (Pubitemid 39362512)
65. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006;10:39-50. (Pubitemid 44018087)
66. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, et al. Structure of the extracellular region of HER-2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60. (Pubitemid 36227628)
67. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Cleavage of HER-2 ectodomain is a pervana-date-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 1999;59:1196-201. (Pubitemid 29136246)
68. Volas GH, Leitzel K, Teramoto Y, Grossberg H, Demers L, Lipton A. Serial serum c-erbB-2 levels in patients with breast carcinoma. Cancer 1996;78:267-72. (Pubitemid 26234569)
69. Luftner D, Schnabel S, Possinger K. c-erbB-2 in serum of patients receiving fractionated paclitaxel chemotherapy. Int J Biol Markers 1999;14:55-9. (Pubitemid 29312987)
70. Molina R, Jo J, Filella X, Bruix J, Castells A, Hague M, et al. Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumor Biol 1997;18:88-96.
71. Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jager W. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 1997;43:87-95. (Pubitemid 27090870)
72. Fehm T, Gebauer G, Jager W. Clinical utility of serial serum c-erB-2 determinations in the follow-up of breast cancer patients. Breast Cancer Res Treat 2002;75:97-106. (Pubitemid 34994945)
73. Hosono M, Saga T, Sakahara H, Kobayashi H, Shirato M, Endo K, et al. Construction of immunoradiometric assay for circulating c-erbB-2 protooncogene product in advanced breast cancer patients. Jpn J Cancer Res 1993;84:147-52. (Pubitemid 23099450)
74. Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, et al. Circulating HER-2/neu extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000;6:2356-62. (Pubitemid 30399203)
75. Schwarz MK, Smith C, Schwartz DC, Dnistrian A, Neiman I. Monitoring therapy by serum HER-2/neu. Int J Biol Markers 2000;15:324-9. (Pubitemid 32041146)
76. Payne RC, Allard JW, Anderson-Mauser L, Humphreys JD, Tenney DY, Morris DL. Automated assay for HER-2/neu in serum. Clin Chem 2000;46:175-82. (Pubitemid 30104240)
77. Cook GB, Neamann IB, Goldblatt JL, Cambetas DR, Hussain M, Lüftner D, et al. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res 2001;21:1465-70. (Pubitemid 32494167)
78. Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, et al. Evaluation of serum HER-2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol 2008;19:883-90. (Pubitemid 351627302)
79. Thirveni K, Deshmane V, Bapsy PP, Krishnamoorthy L, Ramaswamy G. Clinical utility of serum human epidermal recep-tor-2 neu detection in breast cancer patients. Indian J Med Res 2007;125:137-42. (Pubitemid 46563827)
80. Mansour OA, Zekri AR, Harvey J, Teramoto Y, El-Ahamady O. Tissue and serum c-erbB-2 and tissue EGFR in breast carcinoma: three year follow-up. Anticancer Res 1997;17:3101-6.
81. Breuer B, Smith S, Thor A, Edgerton S, Osborne MP, Minick R, et al. ErbB-2 protein in sera and tumors of breast cancer patients. Br Cancer Res Tr 1996;43:47-95.
82. Kong SY, Kang JH, Kwon Y, Kang HS, Chung KW, Kang SH, et al. Serum HER-2/neu concentrations in patients with primary breast cancer. J Clin Pathol 2006,59:373-6.
83. Motoo Y, Sawabu N, Yamaguchi Y, Mouri I, Yamakawa O, Watanabe H, et al. Serum levels of c-erbB-2 protein in digestive diseases. J Gastroenterol 1994;29:616-20. (Pubitemid 24308412)
84. Narita T, Funahaschi H, Satoh T, Takagi H. C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 1992;24:97-102. (Pubitemid 23063892)
85. Osman I, Mikhail M, Shuch B, Clute M, Cheli CD, Ghani F, et al. Serum levels of Shed HER2/neu protein in men with prostate cancer correlate with disease progression. J Urol 2005;174:2174-7. (Pubitemid 41611768)
86. Isola JJ, Holli K, Oksa H, Teramoto Y, Kallioniemi OP. Elevated erb-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 1994;73:652-8. (Pubitemid 24046607)
87. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Muñoz M, et al. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer: utility in prognosis. Anticancer Res 1996;16:2295-3000.
88. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Muñoz M, et al. C-erbB-2 oncoprotein, CEA and CA 15.3 in patients with breast cancer: prognostic value. Br Cancer Res Treat 1998;51:109-19. (Pubitemid 28561416)
89. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, et al. The prognostic significance of amplification and overexpression of c-met and C-erbB-2 in human gastric carcinomas. Cancer 1999;85:1894-902. (Pubitemid 29202761)
90. Ohguri T, Sato Y, Koizumi W, Saigenji K, Kameya T. An immu-nohistochemical study of c-erB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erB-2 protein really a prognostic indicator. Int J Cancer 1993;53:75-9. (Pubitemid 23018426)
91. Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L, et al. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 1992;10:1436-43. (Pubitemid 23059927)
92. McKenzie SJ, De Sombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, et al. Serum levels of HER-2/neu (C-erbB2) correlate with overexpression of p184 neu in human ovarian cancer. Cancer 1993;71:3942-6. (Pubitemid 23172974)
93. Gregorc V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, et al. Effects of Gefitinib on serum epidermal growth factor receptor and HER-2/neu in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004;15:6006-12. (Pubitemid 39287505)
94. Chen CH, Tsai TL, Yang YS, Tsai CC. Studies of the serum HER-2/neu and squamous cell carcinoma-related antigen expression in patients with oral squamous cell carcinoma. J Oral Pathol Med 2007;36:83-7. (Pubitemid 46089308)
95. Meden H, Marx D, Schauer A, Wutte W, Kuhn W. Prognostic sig-nificance of p105 (c-erbB-2 HER-2/neu) serum levels in patients with ovarian cancer. Anticancer Res 1997;17:757-60. (Pubitemid 27105564)
96. Tsigris C, Karayannakis AJ, Zbar A, Syrigos KN, Baibas N, Diamantis T, et al. Clinical significance of serum and urinary c-erb-B-2 levels in colorectal cancer. Cancer Lett 2002;184:215-22. (Pubitemid 34804507)
97. Ardizzoni A, Cafferata MA, Paganuzzi M, Filiberti R, Marroni P, Neri M, et al. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced non-small cell lung carcinoma. Cancer 2001;92:1896-904. (Pubitemid 32952509)
98. Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with HER-2 overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with HER-2 overexpressing disease. Lung Cancer 2004;44:99-110. (Pubitemid 38317266)
99. Shariat SF, Bensalah K, Karam JA, Roehrborn CG, Gallina A, Lotan Y, et al. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostatic cancer. Clin Cancer Res 2007;13:5377-94.
100. Carles J, Lloreta J, Salido M, Font A, Suarez M, Baena V, et al. HER-2/neu expression in prostate cancer: a dynamic process? Clin Cancer Res 2004;10:4742-5. (Pubitemid 38955525)
101. Okegawa T, Kinjo M, Nutuhara K, Higashihara E. Pretreatment serum levels of HER/neu as prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol 2006;13:1197-201. (Pubitemid 44410909)
102. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor receptor with disease relapse and progression to androgen independence in human prostate cancer. Clin Cancer Res 2002;8:3438-44. (Pubitemid 35340719)
103. Calvo BF, Levine AM, Marcos M, Collins QF, Iacocca MV, Caskey LS, et al. Human epidermal receptor expression in prostate cancer. Clin Cancer Res 2003;9:1087-97. (Pubitemid 36323716)
104. Lara PN Jr, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Kauderer C, et al. HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the Californian Cancer Consortium Screening Trial. Cancer 2002;94:2584-9. (Pubitemid 34478071)
105. Myers RB, Brown D, Oelschlager DK, Waterbor JW, Marshall ME, Srivastava S, et al. Elevated serum levels of p105 (erbB-2) in patients with advanced-stage prostatic adenocarcinoma. Int J Cancer 1996;69:398-402. (Pubitemid 26384110)
106. Wu JT, Astgill ME, Zhang P. Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers. J Clin Lab Anal 1993;7:31-40. (Pubitemid 23016809)
107. Domingo-Domenech J, Fernandez PL, Filella X, Martinez-Fernandez A, Molina R, Fernandez E, et al. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol 2008;19:269-75. (Pubitemid 351201707)
108. Fontana X, Ferrari P, Namer M, Peysson R, Salomon C, Bussiere C. C-erbB2 gene amplification and serum level of c-erb-B2 oncoprotein at primary breast cancer diagnosis. Anticancer Res 1994; 14: 2099-104.
109. Chearskul S, Bhothisuwan K, Ornrhebroi S, Churintrapun M, Ornrhebroi S, Klinsala N, et al. Serum c-erbB-2 protein in breast cancer patients. J Med Assoc Thai 2000;83:886-93.
110. Imoto S, Kitoh T, Hasebe T. Serum c-erbB2 levels in monitoring of operable breast cancer patients. Jpn J Clin Oncol 1999;29:336-9.
111. Mazouni CH, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, et al. Kinetics of serum HER-2/neu changes in patients with HER-2/neu positive primary breast cancer after initiation of primary chemotherapy. Cancer 2007;109:496-501. (Pubitemid 46190957)
112. Molina R, Auge JM, Escudero JM, Filella X, Zanon G, Pahisa J, et al. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumor Biol 2010;31:171-80.
113. Kandl H, Seymour L, Bezwoda WR. Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 1994;70:739-42. (Pubitemid 24305613)
114. Nunes RA, Harris LN. The HER-2 extracellular domain as prognostic and predictive factor in breast cancer. Clin Breast Cancer 2002;3:125-35.
115. Dittadi R, Zancan M, Perasole A, Gion M. Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay. Int J Biol Markers 2001;16:255-61. (Pubitemid 34168385)
116. Saghatchian M, Guepratte S, Hacene K, Neumann R, Floiras JL, Pichon MF. Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers 2004;19:14-22. (Pubitemid 38515007)
117. Sugano K, Ushiama M, Fukutomi T, Tsuda H, Kitoh T, Ohkura H. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer 2000;89:329-36. (Pubitemid 30620285)
118. Fehm T, Jager W, Kramer S, Sohn C, Solomayer E, Wallwiener D, et al. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res 2004;24:1987-92. (Pubitemid 38954622)
119. Molina R, Filella X, Zanon G, Pahisa J, Alicarte J, Muñoz M, et al. Prospective evaluation of tumor markers (c-erbB-2 onco-protein, CEA and CA 15.3) in patients with locoregional breast cancer. Anticancer Res 2003;23:1043-50. (Pubitemid 36750917)
120. Fehm T, Maimonis P, Katalanic A, Jager WH. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 1998;55:33-8. (Pubitemid 128707621)
121. Molina R, Jo J, Zanon G, Filella X, Farrus B, Muñoz M, et al. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcino-embryonic antigen and CA15.3. Br J Cancer 1996;74:1126-31. (Pubitemid 26333918)
122. Sugano K, Kawai T, Ishii M, Koyama H, Kitajima M, Kasumi F, et al. Clinical evaluation of serum ErbB-2 protein using enzyme immunoassay (ErbB-2 EIA Nichirei). Gan To Kagaku Ryoho 1994;21:1255-62. (Pubitemid 24248046)
123. Ali SA, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, et al. Relationship of serum HER-2/neu and serum CA 15.3 in patients with metastatic breast cancer. Clin Chem 2002;48:1314-20. (Pubitemid 34809841)
124. Schippinger W, Dandachi N, Regitnig P, Hofmann G, Balic M, Neumann R, et al. The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to antracycline-based neoadjuvant chemotherapy of breast cancer. Am J Clin Pathol 2007;128:630-7. (Pubitemid 47584442)
125. Mehta RR, McDermont JH, Hieken TJ, Marler KC, Patel MK, Wild LD, et al. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J Clin Oncol 1998;16:2409-16. (Pubitemid 28309035)
126. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, et al. Use of serial carcinoembryonic antigen and CA 15-3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995;36:41-8.
127. Nicolini A, Carpi A, Ferrari P, Anselmi L, Spinelli C, Conte M, et al. The role of tumor markers in improving the accuracy of conventional chest X-ray and liver echography in the postoperative detection of thoracic and liver metastases from breast cancer. Br J Cancer 2000;83:1412-7.
128. Yasasever V, Dincer M, Camlica H, Duranyildiz D, Dalay N. Serum c-erbB-2 oncoprotein levels are elevated in recurrent and metastatic breast cancer. Clin Biochem 2000;33:315-7. (Pubitemid 30670185)
129. Molina R, Jo J, Filella X, Zanón G, Farrus B, Muñoz M, et al. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence in breast cancer patients. Anticancer Res 1999;19:2551-6.
130. Molina R, Farrus B, Filella X, Jo J, Zanón G, Pahisa J, et al. Carcinoembryonic antigen in tissue and serum from breast cancer patients: clinical applications in prognosis and in early diagnosis of relapse. Anticancer Res 1999;19:2557-62. (Pubitemid 29392412)
131. Bewick M, Chadderton T, Conlon M, Lafrenie R, Morris D, Stewart D, et al. Expression of c-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Bone Marrow Transpl 1999;24:377-84. (Pubitemid 29403443)
132. Carney WP. The emerging role of monitoring serum HER-2/neu oncoprotein levels in women with metastatic breast cancer. Lab Med 2003;34:58-64. (Pubitemid 36197260)
133. Hudelist G, Kostler W, Czerwenka K, Kubista E, Singer CF. Predicting the clinical course of breast cancer patients undergoing trastuzumab-based therapy: an outlook. Methods Find Exp Clin Pharmacol 2004;3:201-10. (Pubitemid 38659550)
134. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER2 overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-8. (Pubitemid 34273269)
135. Revillion F, Hebbar M, Bonneterre J, Peyrat JP. Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients. Eur J Cancer 1996:32:231-4.
136. Luftner D, Like C, Possinger K. Serum HER-2/neu in the management of breast cancer patients. Clin Biochem 2003;36:233-40. (Pubitemid 36700452)
137. Robertson JF, Jaeger W, Syzmendera JJ, Selby C, Coleman R, Howell A, et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumor markers. European Group for Serum Tumor Markers in Breast Cancer. Eur J Cancer 1999;35:47-53. (Pubitemid 29079490)
138. Dnistrian AM, Schwartz MK, Schwartz DC, Ghani F, Kish L. Significance of serum HER-2/neu oncoprotein, CA 15.3 and CEA in the clinical evaluation of metastatic breast cancer. J Clin Ligand Assay 2003;25:215-20.
139. Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, et al. Cancer and Leukemia Group. Cancer and Leukemia Group B. Circulating HER-2/erbB-2-/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 2001;7:2703-11. (Pubitemid 32911374)
140. Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross H Á, et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005;104:257-63. (Pubitemid 40993251)
141. Schippinger W, Regitnit P, Bauernhofer T, Ploner F, Hofmann G, Krippl P, et al. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. Oncol Rep 2004;11:1331-6.
142. Cheung KL, Pinder SE, Paish C, Sadozye AH, Chan SY, Evans AJ, et al. The role of blood tumor marker measurement (using a biochemical index score and c-erB2) in directing chemotherapy in metastatic breast cancer. Int J Biol Markers 2000;15:203-9.
143. Kong SH, Nam BN, Lee KS, Kwon Y, Lee ES, Seong MW, et al. Predicting tissue HER-2 status using serum HER-2 levels in patients with metastatic breast cancer. Clin Chem 2006;52:1510-5. (Pubitemid 44148313)
144. Köstler WJ, Schwab B, Singer C, Neumann R, Rücklinger E, Brodowicz T, et al. Monitoring of serum HER-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 2004;10:1618-24. (Pubitemid 38435551)
145. Leary AF, Hanna WM, van de Vijver MJ, Penault-Llorca F, Rüschoff J, Osamura RY, et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol 2009;27:1694-705.
146. Molina R. Tumor markers in breast cancer. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK, editors. Tumor markers, physiology, pathobiology, technology, and clinical applications. Washington: AACC Press, 2002:165-88.
147. Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of meta-static breast cancer. Clin Cancer Res 2003;9:4423-34. (Pubitemid 37248400)
148. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-35.
149. Colomer R, Llombart-Crussac A, Lloveras B, Ramos M, Mayordomo JI, Fernández R, et al. High circulating HER2 extracellular domain levels correlate with reduced efficacy of aromatase inhibitor in hormone receptor-positive meta-static breast cancer: a confirmatory prospective study. Cancer 2007;110:2178-85. (Pubitemid 350100738)
150. Classen S, Kopp R, Possinger K, Weidenhagen R, Eiermann W, Wilmanns W. Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy. Tumor Biol 2002;23:70-5. (Pubitemid 34639108)
151. Watanabe N, Mityamoto M, Tokuda Y, Kubota M, Ando Y, Tajima T, et al. Serum c-erbB-2 in breast cancer patients. Acta Oncol 1994;33:901-4.
152. Kath R, Hoffken K, Otte C, Metz K, Scheulen ME, Hülskamp F, et al. The neu-oncogene product in serum and tissue of patients with breast carcinoma. Ann Oncol 1993;4:585-9.
153. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, et al. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in met-astatic breast cancer. Breast Cancer Res Treat 2009;3:503-11.
154. Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, et al. Serum HER-2/neu and response to the aro-matase inhibitor Letrozole versus Tamoxifen. J Clin Oncol 2003;21:1967-72. (Pubitemid 46606385)
155. Krainer M, Brodowicz T, Zellinger R, Wiltschke C, Scholten C, Seifert M, et al. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology 1997;54:475-81. (Pubitemid 27470258)
156. Quaranta M, Daniele A, Coviello M, Savonarola A, Abbate I, Venneri MT, et al. C-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation. Tumori 2006;92:311-7. (Pubitemid 44525308)
157. Salvadori B, Pinzani P, Distante V, Casella D, Bianchi S, Paglierani M, et al. Comparison of pre and postsurgical concentrations of blood HER-2 mRNA and HER-2 extracellular domain reflects HER-2/neu status in early breast cancer. Clin Chem 2005;25:1433-40.
158. Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J, et al. Utility of serum extracelullar domain assessment in clinical decision-making: pooled analysis of tour trials of trastuzumab in metastatic breast cancer. J Clin Oncol 2009;27:1685-93.
159. Köstler WJ, Steger GG, Soleiman A, Schwab B, Singer CF, Tomek S, et al. Monitoring of serum HER-2/neu predicts his-topathological response to neoadjuvant trastruzumab-based therapy for breast cancer. Anticancer Res 2004;24:1127-30. (Pubitemid 38624950)
160. Bethune-Volters A, Labroquere M, Guepratte S, Hacene K, Neumann R, Carney W, et al. Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated meta-static breast cancer patients. Anticancer Res 2004;24:1083-9. (Pubitemid 38624942)
161. Fornier MN, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L, et al. Serum HER-2/neu extracellular domain in met-astatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER-2/neu status by immuno-histochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005;16:234-9. (Pubitemid 40309302)
162. Willsher PC, Beaver J, Pinder S, Bell JA, Ellis IO, Blamey RW, et al. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 1996;40:251-5. (Pubitemid 26336120)
163. Harris LN, Trock B, Berris M, Paik S. The role of ERBB2 extracellular domain in predicting response to chemotherapy in breast cancer patients. Proc Am Soc Clin Oncol 1996;15:108.
164. Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, et al. Clinical utility of serum HER/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 2005;7:436-43.
165. Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Köstler WJ, et al. and the serum HER-2/neu study Group. Cancer 2008;113:1294-301.
166. Hoopmann M, Neumann R, Tanasale T, Schondorf T. HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastasized breast cancer: a longitudinal study. Anticancer Res 2003;23:1031-4. (Pubitemid 36750915)
167. Schondorf T, Hoopmann M, Warm M, Neumann R, Thomas A, Göhring UJ, et al. Serological concentrations of HER-2/neu in breast cancer patients with visceral metastases, receiving tratuzumab therapy predict the clinical course. Clin Chem 2002;48:1360-2. (Pubitemid 34809846)
168. Sandri MT, Johansson H, Colleoni M, Zorzino L, Passerini R, Orlando L, et al. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. Anticancer Res 2004;24:1261-6. (Pubitemid 38624972)
169. Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hösch S, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997;15:2518-25. (Pubitemid 27289880)
170. Luftner DJ, Henschke P, Flath B, Akrivakis C, Schnabel S, Prinz B, et al. Serum HER-2/neu as predictor and monitoring parameter in a phase II study with weekly paclitaxel in meta-static breast cancer. Anticancer Res 2004;24:895-906. (Pubitemid 38625038)
171. Collan J, Sjostrom J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I, et al. Predictive value of c-erbB-2 expression for response to docetaxel or methotrexate-fluoruracil in advanced breast cancer. Breast Cancer Res Treat 1999;57-64.
172. Colomer R, Lloombart-Cusac A, Lluch A, Barnadas A, Ojeda B, Carañana V, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER-2/neu extracellular domain. Ann Oncol 2004;15:201-6. (Pubitemid 38262615)
173. Im SA, Kim SB, Lee HJ, Im YH, Lee KH, Song HS, et al. Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor. Oncol Rep 2005;14:481-7.
174. Muller V, Witzel I, Luck HJ, Köhler G, von Minckwitz G, Möbus V, et al. Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 2004;86:9-18. (Pubitemid 38918894)
175. Harris L, Luftner D, Jager W, Robertson JF. C-erbB-2 in serum of patients with breast cancer. Int J Biol Markers 1999;14:8-15. (Pubitemid 29237570)
176. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, et al. Trastuzumab and vinorelbine as first-line therapy for HER-2/neu overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889-95. (Pubitemid 46621838)
177. Ardavanis A, Kountourakis P, Kyriakou F, Malliou S, Mantzaris I, Garoufali A, et al. Trastuzumab plus paclitaxel or doc-etaxel in HER-2-negative/HER-2 ECD-positive anthracycline and taxane-refractory advanced breast cancer. Oncologist 2008;13:361-9. (Pubitemid 351679914)
178. Lieberman GL, Gourlay P, Klein S, Bruno R. Pharmacokinetic- pharmacodynamic relationships of single agent weekly trastu-zumab in patients with HER-2-overexpressing MBC. Proc Am Soc Clin Oncol 2003;22:20 (abstract 76).
179. Yeung K, Gupta R, Haidak D, Katzen H, Greer J, Quader ML. Weekly herceptin and one hour taxol infusion regimen for human epidermal growth factor receptor-2 over-expressed metastatic breast cancer. Proc Am Soc Clin Oncol 2000;19:142A.
180. Gasparini G, Sarmiento R, Amici S, Longo R, Gattuso D, Zancan M, et al. Gefitnib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cáncer. A phase I study with biological correlate. Ann Oncol 2005;16:1867-73. (Pubitemid 41724274)